Publication date: 21 May 2022
Accreditation expiration date: 21 August 2022
59TH ERA CONGRESS: Independent symposium webcast
Chaired by Claire Sharpe with Pantelis Sarafidis, David Thomas & Ellen Hoogeveen
Watch Prof Claire Sharpe and colleagues in this independent symposium hosted at ERA 2022, where they discussed how to reduce the burden of hyperkalemia whilst maintaining cardio-renal protection for people with chronic kidney disease, with a particular focus on the use of novel K+ binders.
After watching the webcast you will be able to:
|Interpret K+ concentration alongside other patient risk- and clinical-based measures to inform hyperkalemia management and monitoring
|Utilize the emerging evidence and guidelines for the optimization of RAASi therapy when risk of hyperkalemia is high
|Explain the role of newer K+ binders in the management of hyperkalemia whilst maintaining cardio-renal protection
|Balancing cardio-renal protection and hyperkalemia risk in CKD
|Hyperkalemia inpatient management and post-discharge: when should we use K+ binders?
|How can we reduce the burden of hyperkalemia?
Panel discussion and Q&A
All, moderated by Claire Sharpe
King’s College London, UK
Claire Sharpe is Professor and Honorary Consultant in Renal Medicine at King’s College London (KCL)/King’s College Hospital. She graduated in Medicine from University College London and, after specialising in Renal Medicine, undertook a PhD in renal cell signalling at KCL with a Kidney Research UK Clinical Training Fellowship. In 2002 she received an NIHR Clinician Scientist Award and completed her specialist clinical training in 2004. In 2009 she was awarded an NHS/HEFCE Clinical Senior Lectureship and was promoted to Professor in 2019. Claire currently works as a clinical academic dividing her time between teaching, research and caring for patients. She has been involved with medical student teaching and examining for the past 15 years and was appointed as Interim Dean of Medical Education at KCL in January 2022.
Claire’s main research interest is in the study of the pathophysiology of renal fibrosis with a view to discovering new therapeutic targets. Her clinical research interests lie in sickle cell nephropathy and in the epidemiology of cardiovascular disease in patients with chronic kidney disease. She is currently Trustee and Treasurer of the UK Kidney Association.
- Research grant support: AstraZeneca
- Consultancy fees: Novartis Pharmaceuticals, Travere Pharmaceuticals, Vifor Pharmaceuticals
Aristotle University of Thessaloniki, Greece
Doctor Pantelis Sarafidis, MD, MSc, PhD is an Associate Professor in Nephrology at Aristotle University of Thessaloniki, with full clinical duties as Consultant in Nephrology in Hippokration Hospital, Thessaloniki Greece where he is head of the ESH Hypertension Excellence Center. His research activities are focused on hypertension, CVD in patients with CKD, diabetic nephropathy, AKI and polycystic kidney disease. He has authored more than 300 articles in peer-reviewed international medical journals and book chapters in international textbooks, and performed more than 240 lectures in national and international meetings in the areas of Nephrology, Hypertension and related fields. He is currently a reviewer for more than 60 international medical journals. Dr Sarafidis has received several awards and grants from national and international Medical Societies for his research activities.
- Consultancy fees (personal or through Aristotle University of Thessaloniki): Innovis Pharma, Bayer, Primeview, Healthink, Astra-Zeneca and Recor Medical
- Speaker Fees: Winmedica, Boehringer Ingelheim, Bayer, Sanofi, Astra-Zeneca and Genesis Pharma
- Research support: AstraZeneca, Boehringer and Elpen Pharmaceuticals
- Travel/accommodation support: Winmedica and Genesis Pharma
Imperial College London, UK
David Thomas is a Reader in Immunology and Inflammation and an Honorary Consultant Nephrologist. After undertaking the Cambridge MB/PhD programme, he worked as a clinical lecturer with Ken Smith and Gordon Dougan FRS and characterised the novel protein Eros. He was awarded a Wellcome Trust Clinical Research Career Development Fellowship and the Beit Prize in 2017. In April 2019, he moved his laboratory to Imperial College London to take up a Readership. His laboratory works on (i) how Eros controls the phagocyte respiratory burst and other processes in innate and adaptive immunity as well as (ii) the role of reactive oxygen species, derived from a variety of sources, in immunity more generally.
His clinical work is as a nephrologist and internal physician and he is a Consultant Nephrologist at the Hammersmith Hospital. He is involved with, or a co-lead for, several MRC/UKRI-funded studies on the pathogenesis of Covid-19 and vaccine efficacy in renal patients.
- Consultancy fees and honoraria: AstraZeneca and Novartis
Jeroen Bosch Hospital, The Netherlands
Dr Ellen Hoogeveen has more than 25 years professional experience in clinical internal medicine, and more than 15 years experience in clinical nephrology. She also has more than 25 years experience in clinical epidemiologic research. Her research has included work on the effect of obesity on mortality in pre-dialysis, dialysis and kidney transplant patients. In addition, she has conducted research on the effect of hyperhomocysteinemia in patients with and without diabetes on microalbuminuria, cardiovascular morbidity and mortality. She recently studied in the Alpha Omega Trial the preventive effect of fish-oil on kidney function decline in post-myocardial infarction patients. Dr Ellen Hoogeveen is an internist-nephrologist-epidemiologist at the department of nephrology at the Jeroen Bosch Hospital and at the departments of nephrology and clinical epidemiology at the Leiden University Medical Center in The Netherlands.
- No disclosures to declare
The symposium Looking beyond K+ in hyperkalemia for cardiorenal protection, Paris and online, France, 21/05/2022-21/05/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
AstraZeneca has provided an educational grant towards this independent program.